http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2746946-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_fd47318319f20f7f99d9fef1fd3e511b |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-55 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-551 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-337 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-337 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-55 |
| filingDate | 2013-03-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2020-03-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_507a1826d4b54468f6acd587f3969c7d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_af09a8cf4e671d552e7283677cb1b3ae http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_58ee4605f84b389e7e17120cabaae703 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2d5bfd27f78401bc5aa954f6b62145d2 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9f4a4cee5a04ec3cbdbc9335be3af487 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ca4b4b027544ed927d05d52a15579738 |
| publicationDate | 2020-03-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2746946-T3 |
| titleOfInvention | Combination of alisertib and paclitaxel for the treatment of cancer |
| abstract | An Aurora A kinase inhibitor for use in combination with paclitaxel to treat lung cancer in a patient in need thereof, wherein the Aurora A kinase inhibitor is 4 - {[9-chloro-7- ( 2-fluoro-6-methoxyphenyl) -5H-pyrimido [5,4-d] [2] benzazepin-2-yl] amino} -2-methoxybenzoic or a pharmaceutically acceptable salt thereof, where a dose is to be administered twice daily kinase inhibitor Aurora A to the patient on a 28 day dose schedule in combination with a once weekly dose of paclitaxel, where the twice daily dose of kinase inhibitor is administered. Aurora A is from about 30 mg to about 45 mg, and is administered on days 1-3, 8-10, and 15-17 of the 28-day program; and the once weekly dose of paclitaxel administered is from about 50 mg / m2 to about 70 mg / m2, and is administered on days 1, 8 and 15 of the 28-day program; where the term "approximately" modifies a numerical value above and below the value established by a variance of 10%. |
| priorityDate | 2012-03-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 439.